Cleveland health technology company Within3 has secured a new round of financing from a New York venture fund that has previously invested in wireless sensing company CardioMEMS and pharmaceutical company Targacept.
In a vague news release today, Within3 declined to disclose how much Easton Capital invested and only said that the round brought its total aggregate funding to $20 million as it is “gaining significant momentum in the marketplace.”
Within3, which builds private digital collaboration programs and tools for life sciences companies and organizations, has always been relatively mum about financing; it declined to offer details on a 2009 round or on plans for growth in 2011. According to the release, the funding will help the company expand its customer base, which includes 10 of the top 20 pharmaceutical companies plus midtier pharmaceutical companies, medical associations and hospitals, and support infrastructure.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The 8-year-old company has been relatively quiet as of late. Last summer, CEO Lance Hill told MedCity News that the company had experienced a growth spurt between 2010 and 2011, and would be especially focused on global business over the next few years. We heard rumblings of a shakeup in company leadership this summer following the departure of at least three members of the executive team including the chief technology officer, but a representative for the company couldn’t be reached for an update.
John Friedman, managing partner of Easton Capital Group, sits on the board of directors. Easton’s portfolio includes traditional businesses and companies in the life sciences and technology sectors.
[Photo from sheelamohan]
